Drug Trial Radar · NCT06082037
A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction
Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Oct 10, 2023
Primary completion
Jan 29, 2029
Study completion Oct 1, 2030
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Meiji Seika Pharma Co., Ltd.
- First posted
- Oct 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The study duration will be up to 31 weeks for participants not entering the open-label extension (OLE) period and up to 57 weeks for participants entering the OLE period but not the long-term OLE. The treatment duration will be up to 26 weeks for participants not entering the OLE period and up to 52 weeks for participants entering the OLE period but not the long-term OLE. The number of visits will be up to 10 visits for participants not entering the OLE period and up to 16 visits for participants entering the OLE period but not the long-term OLE. For participants who enter the long-term OLE, treatment and study participation will continue with visits every 12 weeks per protocol specifications.
Conditions
- Lung Transplant Rejection
Interventions
BelumosudilDrug
Tablet, Oral
AzithromycinDrug
Depends on pharmaceutical presentation, Oral
PlaceboDrug
Tablet, Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change from baseline to Week 26 in forced expiratory volume in 1 second (FEV1)Time frame: Baseline to Week 26
Locations
85 sites in 20 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham- Site Number : 8400026
Birmingham, Alabama · Recruiting
St. Joseph's Hospital and Medical Center- Site Number : 8400019
Phoenix, Arizona · Recruiting
University of California Los Angeles Medical Center- Site Number : 8400020
Los Angeles, California · Recruiting
Stanford University Medical Center- Site Number : 8400008
Stanford, California · Recruiting
Mayo Clinic in Florida- Site Number : 8400031
Jacksonville, Florida · Recruiting
Jackson Memorial Hospital- Site Number : 8400030
Miami, Florida · Recruiting
AdventHealth Orlando- Site Number : 8400023
Orlando, Florida · Completed
Tampa General Hospital - Tampa - General Circle- Site Number : 8400015
Tampa, Florida · Recruiting
Emory University Hospital- Site Number : 8400027
Atlanta, Georgia · Recruiting
Northwestern University- Site Number : 8400003
Chicago, Illinois · Recruiting
Loyola University Medical Center- Site Number : 8400025
Maywood, Illinois · Recruiting
University of Iowa- Site Number : 8400032
Iowa City, Iowa · Recruiting
University of Maryland School of Medicine - Baltimore- Site Number : 8400009
Baltimore, Maryland · Recruiting
Johns Hopkins Hospital- Site Number : 8400034
Baltimore, Maryland · Recruiting
Brigham & Women's Hospital- Site Number : 8400016
Boston, Massachusetts · Completed
University of Michigan Health System - Ann Arbor- Site Number : 8400014
Ann Arbor, Michigan · Recruiting
Corewell Health - Grand Rapids - Michigan Street Northeast- Site Number : 8400010
Grand Rapids, Michigan · Recruiting
Mayo Clinic in Rochester - Minnesota- Site Number : 8400038
Rochester, Minnesota · Recruiting
NYU Perlmutter Cancer Center - Energy Building- Site Number : 8400001
New York, New York · Recruiting
Icahn School of Medicine at Mount Sinai- Site Number : 8400037
New York, New York · Recruiting
Columbia University Irving Medical Center- Site Number : 8400002
New York, New York · Recruiting
Montefiore Medical Center - Moses Campus- Site Number : 8400036
The Bronx, New York · Recruiting
Duke University Medical Center- Site Number : 8400017
Durham, North Carolina · Recruiting
Cleveland Clinic - Cleveland- Site Number : 8400005
Cleveland, Ohio · Recruiting
The Ohio State University- Site Number : 8400028
Columbus, Ohio · Recruiting
Penn Medicine: University of Pennsylvania Health System- Site Number : 8400006
Philadelphia, Pennsylvania · Recruiting
Temple University Hospital- Site Number : 8400007
Philadelphia, Pennsylvania · Recruiting
Vanderbilt University Medical Center- Site Number : 8400018
Nashville, Tennessee · Recruiting
Baylor University Medical Center- Site Number : 8400011
Dallas, Texas · Completed
University of Texas - Southwestern Medical Center- Site Number : 8400013
Dallas, Texas · Recruiting
Baylor College of Medicine- Site Number : 8400024
Houston, Texas · Recruiting
Houston Methodist Hospital- Site Number : 8400021
Houston, Texas · Recruiting
University Health System - San Antonio- Site Number : 8400035
San Antonio, Texas · Recruiting
University of Utah Medical Group- Site Number : 8400039
Salt Lake City, Utah · Recruiting
Inova Fairfax Hospital- Site Number : 8400004
Falls Church, Virginia · Recruiting
Investigational Site Number : 0360003
Darlinghurst, New South Wales, Australia · Recruiting
Investigational Site Number : 0360001
Brisbane, Queensland, Australia · Recruiting
Investigational Site Number : 0360002
Murdoch, Western Australia, Australia · Recruiting
Investigational Site Number : 0400001
Vienna, Austria · Recruiting
Investigational Site Number : 0560001
Leuven, Belgium · Recruiting
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.